Compounds for treating cns disorders
AssigneeSage Therapeutics, Inc.
InventorsMaria Jesus Blanco-Pillado, Francesco G. Salituro, Marshall Lee Morningstar
Life of this patent
Estimating the term…
Abstract
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS-related disorders.
Claims76
1-30. (canceled)
A compound of Formula (I):
- or a pharmaceutically acceptable salt thereof;
- wherein:
- represents a single or double bond, provided if a double bond is present, then one of R6a or R6b is absent and R5 is absent;
- L is selected from the group consisting of:
- wherein A indicates the point of attachment at C17;
- X is —N(R55a)(R55b) or —N(R55b)C(O)(R55a);
- each of R55a and R55b is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —ORA1, —N(RA1)2, —SRA1, —C(═O)RA1, —C(═O)ORA1, —C(═O)SRA1, —C(═O)N(RA1)2, —OC(═O)RA1, —OC(═O)ORA1, —OC(═O)N(RA1)2, —OC(═O)SRA1, —OS(═O)2RA1, —OS(═O)2ORA1, —OS(═O)2N(RA1)2, —N(RA1)C(═O)RA1, —N(RA1)C(═NRA1)RA1, —N(RA1)C(═O)ORA1, —N(RA1)C(═O)N(RA1)2, —N(RA1)C(═NRA1)N(RA1)2, —N(RA1)S(═O)2RA1, —N(RA1)S(═O)2ORA1, —N(RA1)S(═O)2N(RA1)2, —SC(═O)RA1, —SC(═O)ORA1, —SC(═O)SRA1, —SC(═O)N(RA1)2, —S(═O)2RA1, —S(═O)2ORA1, or —S(═O)2N(RA1)2, wherein each instance of RA1 is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to oxygen, a nitrogen protecting group when attached to nitrogen, a sulfur protecting group when attached to sulfur, or two RA1 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring;
- or R55a and R55b may join together with the intervening atoms to form a substituted or unsubstituted heterocyclic ring or a substituted or unsubstituted heteroaryl;
- R3 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
- R5 is hydrogen or methyl;
- each RGA is independently hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 carbocyclyl, substituted or unsubstituted 3- to 6-membered heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to oxygen, nitrogen protecting group when attached to nitrogen, or two RGA groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclyl or heteroaryl ring;
- each of R1a, R1b, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, and R12b is independently hydrogen, halogen, cyano, —NO2, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —ORA1, —N(RA1)2, —SRA1, —C(═O)RA1, —C(═O)ORA1, —C(═O)SRA1, —C(═O)N(RA1)2, —OC(═O)RA1, —OC(═O)ORA1, —OC(═O)N(RA1)2, —OC(═O)SRA1, —OS(═O)2RA1, —OS(═O)2ORA1, —OS(═O)2N(RA1)2, —N(RA1)C(═O)RA1, —N(RA1)C(═NRA1)RA1, —N(RA1)C(═O)ORA1, —N(RA1)C(═O)N(RA1)2, —N(RA1)C(═NRA1)N(RA1)2, —N(RA1)S(═O)2RA1, —N(RA1)S(═O)2ORA1, —N(RA1)S(═O)2N(RA1)2, —SC(═O)RA1, —SC(═O)ORA1, —SC(═O)SRA1, —SC(═O)N(RA1)2, —S(═O)2RA1, —S(═O)2ORA1, or —S(═O)2N(RA1)2, wherein each instance of RA1 is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to oxygen, a nitrogen protecting group when attached to nitrogen, a sulfur protecting group when attached to sulfur, or two RA1 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring;
- each of R6a and R6b is independently hydrogen, halogen, cyano, —NO2, —OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
- or R6a and R6b are joined to form an oxo (═O) group;
- each of R15a, R15b, R16a, and R16b is each independently hydrogen, halogen, —CN, —NO2, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —ORC3, —N(RC3)2, —SRC3, —C(═O)RC3, —C(═O)ORC3, —C(═O)SRC3, —C(═O)N(RC3)2, —OC(═O)RC3, —OC(═O)ORC3, —OC(═O)N(RC3)2, —OC(═O)SRC3, —OS(═O)2RC3, —OS(═O)2ORC3, —OS(═O)2N(RC3)2, —N(RC3)C(═O)RC3, —N(RC3)C(═NRC3)RC3, —N(RC3)C(═O)ORC3, —N(RC3)C(═O)N(RC3)2, —N(RC3)C(═NRC3)N(RC3)2, —N(RC3)S(═O)2RC3, —N(RC3)S(═O)2ORC3, —N(RC3)S(═O)2N(RC3)2, —SC(═O)RC3, —SC(═O)ORC3, —SC(═O)SRC3, —SC(═O)N(RC3)2, —S(═O)2RC3, —S(═O)2ORC3, or —S(═O)2N(RC3)2, wherein each instance of RC3 is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl, an oxygen protecting group when attached to oxygen, a nitrogen protecting group when attached to nitrogen, a sulfur protecting group when attached to sulfur, or two RC3 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring;
- R18 is substituted or unsubstituted alkyl;
- R19 is hydrogen or substituted or unsubstituted alkyl;
- and
- t is 2 or 3.
A compound of Formula (VIa) or Formula (VIb):
- or a pharmaceutically acceptable salt thereof;
- wherein:
- represents a single or double bond, provided if a double bond is present, then one of R6a or R6b is absent and R5 is absent;
- L is selected from the group consisting of:
- wherein A indicates the point of attachment at C17;
- X is —N(R55a)(R55b) or —N(R55b)C(O)(R55a);
- each of R55a and R55b is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —ORA1, —N(RA1)2, —SRA1, —C(═O)RA1, —C(═O)ORA1, —C(═O)SRA1, —C(═O)N(RA1)2, —OC(═O)RA1, —OC(═O)ORA1, —OC(═O)N(RA1)2, —OC(═O)SRA1, —OS(═O)2RA1, —OS(═O)2ORA1, —OS(═O)2N(RA1)2, —N(RA1)C(═O)RA1, —N(RA1)C(═NRA1)RA1, —N(RA1)C(═O)ORA1, —N(RA1)C(═O)N(RA1)2, —N(RA1)C(═NRA1)N(RA1)2, —N(RA1)S(═O)2RA1, —N(RA1)S(═O)2ORA1, —N(RA1)S(═O)2N(RA1)2, —SC(═O)RA1, —SC(═O)ORA1, —SC(═O)SRA1, —SC(═O)N(RA1)2, —S(═O)2RA1, —S(═O)2ORA1, or —S(═O)2N(RA1)2, wherein each instance of RA1 is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to oxygen, a nitrogen protecting group when attached to nitrogen, a sulfur protecting group when attached to sulfur, or two RA1 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring;
- or R55a and R55b may join together with the intervening atoms to form a substituted or unsubstituted heterocyclic ring or a substituted or unsubstituted heteroaryl;
- R3 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
- R5 is hydrogen or methyl;
- each RGA is independently hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 carbocyclyl, substituted or unsubstituted 3- to 6-membered heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to oxygen, nitrogen protecting group when attached to nitrogen, or two RGA groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclyl or heteroaryl ring;
- each of R1a, R1b, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, and R12b is independently hydrogen, halogen, cyano, —NO2, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —ORA1, —N(RA1)2, —SRA1, —C(═O)RA1, —C(═O)ORA1, —C(═O)SRA1, —C(═O)N(RA1)2, —OC(═O)RA1, —OC(═O)ORA1, —OC(═O)N(RA1)2, —OC(═O)SRA1, —OS(═O)2RA1, —OS(═O)2ORA1, —OS(═O)2N(RA1)2, —N(RA1)C(═O)RA1, —N(RA1)C(═NRA1)RA1, —N(RA1)C(═O)ORA1, —N(RA1)C(═O)N(RA1)2, —N(RA1)C(═NRA1)N(RA1)2, —N(RA1)S(═O)2RA1, —N(RA1)S(═O)2ORA1, —N(RA1)S(═O)2N(RA1)2, —SC(═O)RA1, —SC(═O)ORA1, —SC(═O)SRA1, —SC(═O)N(RA1)2, —S(═O)2RA1, —S(═O)2ORA1, or —S(═O)2N(RA1)2, wherein each instance of RA1 is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to oxygen, a nitrogen protecting group when attached to nitrogen, a sulfur protecting group when attached to sulfur, or two RA1 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring;
- each of R6a and R6b is independently hydrogen, halogen, cyano, —NO2, —OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
- or R6a and R6b are joined to form an oxo (═O) group;
- each of R15a, R15b, R16a, and R16b is each independently hydrogen, halogen, —CN, —NO2, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —ORC3, —N(RC3)2, —SRC3, —C(═O)RC3, —C(═O)ORC3, —C(═O)SRC3, —C(═O)N(RC3)2, —OC(═O)RC3, —OC(═O)ORC3, —OC(═O)N(RC3)2, —OC(═O)SRC3, —OS(═O)2RC3, —OS(═O)2ORC3, —OS(═O)2N(RC3)2, —N(RC3)C(═O)RC3, —N(RC3)C(═NRC3)RC3, —N(RC3)C(═O)ORC3, —N(RC3)C(═O)N(RC3)2, —N(RC3)C(═NRC3)N(RC3)2, —N(RC3)S(═O)2RC3, —N(RC3)S(═O)2ORC3, —N(RC3)S(═O)2N(RC3)2, —SC(═O)RC3, —SC(═O)ORC3, —SC(═O)SRC3, —SC(═O)N(RC3)2, —S(═O)2RC3, —S(═O)2ORC3, or —S(═O)2N(RC3)2, wherein each instance of RC3 is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl, an oxygen protecting group when attached to oxygen, a nitrogen protecting group when attached to nitrogen, a sulfur protecting group when attached to sulfur, or two RC3 groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclic ring;
- R19 is hydrogen or substituted or unsubstituted alkyl;
- and
- each r is independently 2 or 3.
A compound selected from:
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt of claim 1, and a pharmaceutically acceptable excipient.
A method of modulating a GABAA receptor in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound or pharmaceutically acceptable salt of claim 1.
A method of treating a CNS-related disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound or pharmaceutically acceptable salt of claim 1.
A method of inducing sedation and/or anesthesia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound or pharmaceutically acceptable salt of claim 1.
Dependencies are inferred from the claim text.